Gapping up on strong earnings/guidance:
Gapping up on strong earnings/guidance:
NGA +22.3%, CRNT +13.3%, XFML +9.9%, RSH +8.1%, VSH +8.0%, HERO +6.8%, BEAV +5.1%... Other news: ISE +43.3% (Deutsche Boerse contemplating bid for ISE for approx. $2.8 bln cash, or $67.50 a share), NPTH +26.2% (to be acquired by GB for $14.38 per share in cash), ISPH +24.0% (announced FDA approval of AzaSite), IOTN +19.7% (positive Cramer mention), IDIX +14.7% (announces European Commission approved Sebvio), AVNR +14.4%, SGMO +13.8% (announces research and license agreement with Genentech), ISV +13.0% (announces FDA approval for AzaSite; approval triggers $19 mln milestone payment), NTWK +7.8% (NTWK Pakistan subsidiary reports Q3 results).
NGA +22.3%, CRNT +13.3%, XFML +9.9%, RSH +8.1%, VSH +8.0%, HERO +6.8%, BEAV +5.1%... Other news: ISE +43.3% (Deutsche Boerse contemplating bid for ISE for approx. $2.8 bln cash, or $67.50 a share), NPTH +26.2% (to be acquired by GB for $14.38 per share in cash), ISPH +24.0% (announced FDA approval of AzaSite), IOTN +19.7% (positive Cramer mention), IDIX +14.7% (announces European Commission approved Sebvio), AVNR +14.4%, SGMO +13.8% (announces research and license agreement with Genentech), ISV +13.0% (announces FDA approval for AzaSite; approval triggers $19 mln milestone payment), NTWK +7.8% (NTWK Pakistan subsidiary reports Q3 results).
posted by Gordengekko at 8:56 AM
0 Comments:
Post a Comment
<< Home